biocrea expands management team
This article was originally published in Scrip
German CNS therapeutics company, biocrea GmbH, a management buy-out from Finland's Biotie Therapies, has expanded its management team by appointing Dr Martin Gunthorpe as Chief Scientific Officer, Mr Viktor Viehweg to the position of Chief Financial Officer, and Professor Simon Ward to Executive Vice President Chemistry & Development. Dr Gunthorpe joins biocrea from GlaxoSmithKline, where he was Head of Electrophysiology and Project Leader in the Neurosciences Centre of Excellence for Drug Discovery. Professor Ward also joins biocrea from GSK, where he has been Assistant Director and a member of business unit & chemistry leadership teams, he also holds the Chair of Medicinal Chemistry at the University of Sussex, UK. Mr Viehweg was most recently Head of Corporate Strategy at Moscow-based Sibur Ltd.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.